US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARK Genomic Revolution ETF

49.45

+1.813.80%

Post-market: 49.650.2000+0.40%19:58 EDT

Volume:11.30M

Turnover:555.26M

Market Cap:2.00B

PE:- -

High:49.56

Open:47.93

Low:47.55

Close:47.64

52wk High:49.56

52wk Low:24.20

Shares:40.35M

Float Shares:40.35M

Volume Ratio:3.27

T/O Rate:28.00%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Absci Q2 Revenue USD 318 Thousand VS. Ibes Estimate USD 1.17 Million

THOMSON REUTERS

Absci Q2 Operating Expenses USD 34.476 Million

THOMSON REUTERS

Press Release: Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Forterra Confirms Total Voting Rights in Share Capital

Jiangsu Sidike New Materials Establishes Shanghai Subsidiary

MT Newswires Live

SpaceX Earnings Highlights from Cathie Wood's ARK Invest

Benzinga Earnings

10x Genomics Inc : Canaccord Genuity Raises Target Price to $60 from $50

THOMSON REUTERS

10x Genomics price target raised to $47 from $42 at Piper Sandler

NAC Co., Ltd. Issues Q1 FY2027 Results and Mid-Term Plan Overview

Tanabe Consulting Group Outlines Q1 Results and Long-Term Strategy

Business Engineering Corp Outlines FY2026 1Q Results and AI Growth Strategy

KLab Releases FY2026 Q2 Presentation, Emphasizes Uncertainty in Outlook

Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test

Simply Wall St.

Wood: Job Data Doesn't Signal Recession, AI Is Driving the U.S. Into a New Cycle of Deflation and High Productivity

Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network

Simply Wall St.

10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash

Simply Wall St.

Bonterra Launches Tradable Rights Offering to Fund Share Issuance

MYR Group Highlights Growth and Strategic Positioning

LCNB Highlights Investor Presentation Under Regulation FD Disclosure

Absci Files Form 3 for CMO, Head of R&D Somaratne Ransi Mudalinayake

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ARKG/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ARKG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARKG\",,,,,undefined,":{"symbol":"ARKG","market":"US","secType":"STK","nameCN":"ARK Genomic Revolution ETF","latestPrice":49.45,"timestamp":1787342400000,"preClose":47.64,"halted":0,"volume":11296438,"hourTrading":{"tag":"盘后","latestPrice":49.65,"preClose":49.45,"latestTime":"19:58 EDT","volume":56956,"amount":2819630.4284,"timestamp":1787356682401,"change":0.2,"changeRate":0.004044,"amplitude":0.013124},"delay":0,"changeRate":0.03799328295549963,"floatShares":40350000,"shares":40350000,"eps":0,"marketStatus":"Market Closed","change":1.81,"latestTime":"08-21 16:00:00 EDT","open":47.93,"high":49.56,"low":47.545,"amount":555257262.42759,"amplitude":0.042296,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":47.64,"sharesOutstanding":39900000,"nav":47.644442,"aum":1979577971.9,"bidAskSpread":0.000209,"preHourTrading":{"tag":"盘前","latestPrice":47.9,"preClose":47.64,"latestTime":"09:26 EDT","volume":20719,"amount":999516.4672600001,"timestamp":1787318780899,"change":0.26,"changeRate":0.005458,"amplitude":0.024291},"postHourTrading":{"tag":"盘后","latestPrice":49.65,"preClose":49.45,"latestTime":"19:58 EDT","volume":56956,"amount":2819630.4284,"timestamp":1787356682401,"change":0.2,"changeRate":0.004044,"amplitude":0.013124},"volumeRatio":3.2679704792909074,"impliedVol":0.4949,"impliedVolPercentile":0.4104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARKG\",,,,,undefined,":{"symbol":"ARKG","floatShares":40350000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.2679704792909074,"shares":40350000,"dividePrice":0,"high":49.56,"amplitude":0.042296,"preClose":47.64,"low":47.545,"week52Low":24.2,"pbRate":"--","week52High":49.56,"institutionHeld":0,"latestPrice":49.45,"eps":0,"divideRate":0,"volume":11296438,"delay":0,"ttmEps":0,"open":47.93,"prevYearClose":28.97,"prevWeekClose":43.45,"prevMonthClose":38.56,"prevQuarterClose":42.06,"fiveDayClose":43.45,"twentyDayClose":37.81,"sixtyDayClose":32.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARKG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-12-29","symbol":"ARKG","amount":0.38239,"defaultRemindTime":1640788200000,"name":"ARK Genomic Revolution Multi-Sector ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000},{"market":"US","date":"2020-12-29","symbol":"ARKG","amount":0.36456,"name":"ARK Genomic Revolution Multi-Sector ETF","recordDate":"2020-12-31","payableDate":"2020-12-30","currency":"USD","type":"dividend","dateTimestamp":1609218000000},{"market":"US","date":"2019-12-27","symbol":"ARKG","amount":1.05395,"name":"ARK Genomic Revolution Multi-Sector ETF","recordDate":"2019-12-31","payableDate":"2019-12-30","currency":"USD","type":"dividend","dateTimestamp":1577422800000},{"market":"US","date":"2018-12-27","symbol":"ARKG","amount":0.26999,"name":"ARK Genomic Revolution Multi-Sector ETF","recordDate":"2018-12-31","payableDate":"2018-12-28","currency":"USD","type":"dividend","dateTimestamp":1545886800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARKG\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2018-12-31","value":0.26999,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":1.05395,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.36456,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":0.38239,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARKG\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARKG\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658948691","title":"Absci Q2 Revenue USD 318 Thousand VS. Ibes Estimate USD 1.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948691?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXP8JG9N:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4539","ABSI","BK4139","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948610","title":"Absci Q2 Operating Expenses USD 34.476 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948610?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXP8JG9N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ARKG","ABSI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948282","title":"Press Release: Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948282","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948282?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478700,"startTime":"0","endTime":"0","summary":"Announced positive interim Phase 1 data from the HEADLINE trial of ABS-201Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & CompanyCash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026  -- Absci Corporation , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.\"The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next,\" said Sean McClain, Founder and CEO. \"We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027. These results have the potential to demonstrate ABS-201's regenerat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4604","BK4588","PK","QTOC","BK4139","ABSI","ARKG","TM","BK4181","BK4539","BK4121","BK4555","AIPO","CHAT","VTHR","KBWY","BK4585","AGIX","BK4099","03160","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658067996","title":"Forterra Confirms Total Voting Rights in Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2658067996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658067996?lang=en_us&edition=fundamental","pubTime":"2026-08-11 17:34","pubTimestamp":1786440859,"startTime":"0","endTime":"0","summary":"Forterra ( ($GB:FORT) ) has issued an announcement. Forterra plc operates in the U.K. building materials sector, manufacturing clay bricks, concret...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/forterra-confirms-total-voting-rights-in-share-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/forterra-confirms-total-voting-rights-in-share-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLBI","BK4588","BK4544","DVXB","PKB","PAVE","TRUM","BK4535","TSS","XLB","EES","ARKG","FTIF","BK4585","CCNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658996796","title":"Jiangsu Sidike New Materials Establishes Shanghai Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658996796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658996796?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:48","pubTimestamp":1786430905,"startTime":"0","endTime":"0","summary":"Jiangsu Sidike New Materials Science & Technology (SHE:300806) established a wholly-owned subsidiary, Sidike Shanghai New Material Technology, with registered capital of 10 million yuan, according to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4544","300806","BK4585","UYM","BK0220","BK4588","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958038","title":"SpaceX Earnings Highlights from Cathie Wood's ARK Invest","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958038","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658958038?lang=en_us&edition=fundamental","pubTime":"2026-08-11 01:16","pubTimestamp":1786382210,"startTime":"0","endTime":"0","summary":"ARK Invest sees SpaceX stock selloff as short-term, as investors overlooked its $28.5 trillion total addressable market.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/08/61084513/spacex-earnings-highlights-from-cathie-woods-ark-invest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXYZ","ARKK","ARKQ","ARKG","SPCU","SPCX","XOVR","ARKF","SARK","SNK","ARKX","SPAL","ARKW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993450","title":"10x Genomics Inc : Canaccord Genuity Raises Target Price to $60 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993450?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:47","pubTimestamp":1786369626,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","TXG","BK4548","LU1861558580.USD","BK4585","BK4121","ARKG","BK4588","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658388933","title":"10x Genomics price target raised to $47 from $42 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2658388933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658388933?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:20","pubTimestamp":1786360847,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $47 from $42 and keeps a Neutral rating on the shares following quarterly res...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/10x-genomics-price-target-raised-to-47-from-42-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/10x-genomics-price-target-raised-to-47-from-42-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TXG","BK4121","LU1861559042.SGD","LU1861558580.USD","BK4548","FMED","BK4588","BK4585","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518985","title":"NAC Co., Ltd. Issues Q1 FY2027 Results and Mid-Term Plan Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518985?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:18","pubTimestamp":1786346315,"startTime":"0","endTime":"0","summary":"An announcement from NAC Co., Ltd. ( ($JP:9788) ) is now available. NAC Co., Ltd. released reference materials on its financial results for the fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nac-co-ltd-issues-q1-fy2027-results-and-mid-term-plan-overview?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nac-co-ltd-issues-q1-fy2027-results-and-mid-term-plan-overview?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4544","NAC","ARKG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608602","title":"Tanabe Consulting Group Outlines Q1 Results and Long-Term Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608602","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658608602?lang=en_us&edition=fundamental","pubTime":"2026-08-10 12:23","pubTimestamp":1786335810,"startTime":"0","endTime":"0","summary":"The latest announcement is out from TANABE CONSULTING GROUP CO. LTD ( ($JP:9644) ). Tanabe Consulting Group released supplementary materials for it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tanabe-consulting-group-outlines-q1-results-and-long-term-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tanabe-consulting-group-outlines-q1-results-and-long-term-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ARKG","BK4544","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658560412","title":"Business Engineering Corp Outlines FY2026 1Q Results and AI Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658560412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658560412?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:23","pubTimestamp":1786332233,"startTime":"0","endTime":"0","summary":"Business Engineering Corporation ( ($JP:4828) ) just unveiled an update. Business Engineering Corporation released briefing materials for its first...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/business-engineering-corp-outlines-fy2026-1q-results-and-ai-growth-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/business-engineering-corp-outlines-fy2026-1q-results-and-ai-growth-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTY","CHAT","VTHR","BK4544","ARKG","BK4585","AGIX","QTOC","AIPO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604105","title":"KLab Releases FY2026 Q2 Presentation, Emphasizes Uncertainty in Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604105","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658604105?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:22","pubTimestamp":1786332170,"startTime":"0","endTime":"0","summary":"KLab Inc. ( ($JP:3656) ) has issued an announcement. KLab Inc. has released its presentation materials for the second quarter of fiscal year 2026, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/klab-releases-fy2026-q2-presentation-emphasizes-uncertainty-in-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/klab-releases-fy2026-q2-presentation-emphasizes-uncertainty-in-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4544","ARKG","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670176","title":"Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670176?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:30","pubTimestamp":1786293017,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers.\nSee our latest analysis for Tempus AI.\nTempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TEM","LU1861559042.SGD","BK4611","BK4121","BK4613","ARKG","HEAL","LU1861558580.USD","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169023813","title":"Wood: Job Data Doesn't Signal Recession, AI Is Driving the U.S. Into a New Cycle of Deflation and High Productivity","url":"https://stock-news.laohu8.com/highlight/detail?id=1169023813","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169023813?lang=en_us&edition=fundamental","pubTime":"2026-08-09 22:30","pubTimestamp":1786285839,"startTime":"0","endTime":"0","summary":"Cathie Wood, founder of the renowned investment firm ARK Invest, stated on the 8th that recent U.S. employment data, which has sparked market concerns, actually masks deeper structural economic...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBIL","BPI","CBOO","PBDC","ARKB","VDC","USHY","BRRR","TBIL","MINT","TSYW","BWX","UBT","MUNX","ISHG","AIPO","ARKK","ARKQ","BK4544","BTF","BK4588","XLRE","ZVOL","AGIX","DEFI","CHAT","BTCO","BITI","MNRS","NCPB","CBXJ","BOND","TFJL","BITX","ARKF","BETE","BITO","SHY","CBTY","SCHO","XLRI","BCCC","CBXY","CBOA","IBIT","SHV","BFAP","BBSB","BSV","SBIT","BAGY","ITB","DBA","BTC","BK4535","BBIB","XLP","SARK","SGOV","YBTC","FBTC","CBXA","BBLB","TBT","TLTW","XHB","GOVT","TLTX","BTCC","ARTY","BITY","BK4594","XRT","IGOV","QBF","IEI","ZROZ","VTHR","BTCZ","GOLY","BETH","CBTJ","EZBC","CBXO","QTOC","CBOJ","HODL","DFII","BK4601","DBND","BWZ","ARKW","BTFX","ARKG","TBJL","CBTO","CBTA","TYO","BK4585","MAXI","CBOY","EDV","BTRN","TLT","IEF","BTCW","VCSH","IYR","CIVG","NAIL","FLGV","BTCL","VCIT","DRV","BITU","GBTC","TLTI","XBTY","BITB","BFJL","DRN","CGUS","BK4550","TLH","VGLT","ARKX","SCHH","BTCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657845678","title":"Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2657845678","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657845678?lang=en_us&edition=fundamental","pubTime":"2026-08-08 20:31","pubTimestamp":1786192260,"startTime":"0","endTime":"0","summary":"On 6 August 2026, CellCarta Inc. said it would add Tempus AI to its CDx Commercialization Lab Network, with Tempus using its Tempus Hub to manage provider test ordering, sample routing to CellCarta, and result delivery for oncology-focused companion diagnostics in the U.S.\nThis collaboration links Tempus AI’s ordering and data platform with CellCarta’s development and regulatory capabilities, aiming to close the gap between CDx approval and real-world clinical access for cancer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/why-tempus-ai-tem-is-up-186-after-joining-cellcartas-cdx-com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HEAL","BK4613","LU1861559042.SGD","LU1861558580.USD","TEM","BK4121","ARKG","TEMT","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657419624","title":"10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2657419624","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657419624?lang=en_us&edition=fundamental","pubTime":"2026-08-08 07:46","pubTimestamp":1786146379,"startTime":"0","endTime":"0","summary":"10x Genomics stock jumped 14.1% to about US$52 after its Q2 report, and the move appears to reflect sentiment rather than a sudden profit breakthrough. The company still reported a loss per share and quarterly revenue of US$151 million, so the market is effectively reacting to the quality of the loss, not the absence of it.\nThe key focus for traders is margin and balance sheet resilience. Gross margin improved to roughly 74%, and cash and marketable securities stood at US$552 million. Today’s...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-stock-rally-leans-on-margin-gains-and-cash","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-stock-rally-leans-on-margin-gains-and-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","FMED","TXG","LU1861559042.SGD","BK4548","BK4121","ARKG","LU1861558580.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657862181","title":"Bonterra Launches Tradable Rights Offering to Fund Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657862181","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657862181?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:39","pubTimestamp":1786138788,"startTime":"0","endTime":"0","summary":"BonTerra Resources ( ($TSE:BTR) ) has shared an announcement. Bonterra Resources has mailed materials for its previously announced rights offering ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bonterra-launches-tradable-rights-offering-to-fund-share-issuance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bonterra-launches-tradable-rights-offering-to-fund-share-issuance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4544","ARKG","CLM","BTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629242","title":"MYR Group Highlights Growth and Strategic Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629242?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:20","pubTimestamp":1786137658,"startTime":"0","endTime":"0","summary":"MYR Group ( ($MYRG) ) has issued an announcement. On August 7, 2026, MYR Group Inc. published updated investor presentation materials outlining its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/myr-group-highlights-growth-and-strategic-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/myr-group-highlights-growth-and-strategic-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4544","BK4585","BK4588","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657296486","title":"LCNB Highlights Investor Presentation Under Regulation FD Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2657296486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657296486?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:57","pubTimestamp":1786136257,"startTime":"0","endTime":"0","summary":"LCNB ( ($LCNB) ) just unveiled an announcement. LCNB Corp. disclosed that it plans to use materials identified as Exhibit 99.1 in upcoming meetings...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lcnb-highlights-investor-presentation-under-regulation-fd-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lcnb-highlights-investor-presentation-under-regulation-fd-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","BK4588","BK4544","BK4211","BK4585","LCNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657293016","title":"Absci Files Form 3 for CMO, Head of R&D Somaratne Ransi Mudalinayake","url":"https://stock-news.laohu8.com/highlight/detail?id=2657293016","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657293016?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:54","pubTimestamp":1786136059,"startTime":"0","endTime":"0","summary":"Absci files Form 3 for CMO, Head of R&D Somaratne Ransi MudalinayakeAbsci filed an initial beneficial ownership statement for Somaratne Ransi Mudalinayake, chief medical officer, head of R&D.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL3XZzYr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","ABSI","BK4139","ARKG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}